Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of ($2.03), $0.28 worse than the analyst estimate of ($1.75). Revenue for the quarter came in at $108.8 million versus the consensus estimate of $116.25 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.